Recent advances in understanding Marfan syndrome: Should we now treat surgical patients with losartan?

Journal of Thoracic and Cardiovascular Surgery

Volumn 135, Issue 2, 2008, Pages 389-394

  Matt, Peter ^a,b   Habashi, Jennifer ^a   Carrel, Thierry ^b   Cameron, Duke E ^c   Van Eyk, Jennifer E ^d   Dietz, Harry C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Division of Cardiac Surgery   (Switzerland)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRILLIN 1; LOSARTAN; PLACEBO; PROPRANOLOL; TRANSFORMING GROWTH FACTOR BETA;

AORTA DISSECTION; AORTA ROOT; ARTICLE; CONNECTIVE TISSUE DISEASE; DISEASE COURSE; DRUG DOSE TITRATION; GENE MUTATION; HAPLOTYPE; HUMAN; LUNG DISEASE; MARFAN SYNDROME; MITRAL VALVE PROLAPSE; MYOPATHY; NONHUMAN; PRIORITY JOURNAL; SURGICAL PATIENT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTIC ANEURYSM, THORACIC; COHORT STUDIES; DISEASE MODELS, ANIMAL; FOLLOW-UP STUDIES; GENETIC MARKERS; HUMANS; LOSARTAN; MARFAN SYNDROME; MICE; MICROFILAMENT PROTEINS; RISK ASSESSMENT; SURVIVAL RATE; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME;

EID: 38649094252     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2007.08.047     Document Type: Article

References (31)

1. Judge D.P., and Dietz H.C. Marfan's syndrome. Lancet 366 (2005) 1965-1976
2. Murdoch J.L., Walker B.A., Halpern B.L., Kuzma J.W., and McKusick V.A. Life expectancy and causes of death in the Marfan syndrome. N Engl J Med 286 (1972) 804-808
3. Patel N.D., Williams J.A., Barreiro C.J., Bethea B.T., Fitton T.P., Dietz H.C., et al. Valve-sparing aortic root replacement: early experience with the De Paulis Valsalva graft in 51 patients. Ann Thorac Surg 82 (2006) 548-553
4. Shores J., Berger K.R., Murphy E.A., and Pyeritz R.E. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med 330 (1994) 1335-1341
5. Neptune E.R., Frischmeyer P.A., Arking D.E., Myers L., Bunton T.E., Gayraud B., et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 33 (2003) 407-411
6. Judge D.P., Biery N.J., Keene D.R., Geubtner J., Myers L., Huso D.L., et al. Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. J Clin Invest 114 (2004) 172-181
7. Habashi J.P., Judge D.P., Holm T.M., Cohn R.D., Loeys B.L., Cooper T.K., et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312 (2006) 117-121
8. Cohn R.D., van Erp C., Habashi J.P., Soleimani A.A., Klein E.C., Lisi M.T., et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 13 (2007) 204-210
9. Biery N.J., Eldadah Z.A., Moore C.S., Stetten G., Spencer F., and Dietz H.C. Revised genomic organization of FBN1 and significance for regulated gene expression. Genomics 56 (1999) 70-77
10. Ramirez F. Fibrillin mutations in Marfan syndrome and related phenotypes. Curr Opin Genet Dev 6 (1996) 309-315
11. Collod-Beroud G., Le Bourdelles S., Ades L., Ala-Kokko L., Booms P., Boxer M., et al. Update of the UMD-FBN1 mutation database and creation of an FBN1 polymorphism database. Hum Mutat 22 (2003) 199-208
12. Dietz H.C., Cutting G.R., Pyeritz R.E., Maslen C.L., Sakai L.Y., Corson G.M., et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 352 (1991) 337-339
13. Dietz H.C., and Mecham R.P. Mouse models of genetic diseases resulting from mutations in elastic fiber proteins. Matrix Biol 19 (2000) 481-488
14. Ramirez F., Sakai L.Y., Dietz H.C., and Rifkin D.B. Fibrillin microfibrils: multipurpose extracellular networks in organismal physiology. Physiol Genomics 19 (2004) 151-154
15. Pereira L., Lee S.Y., Gayraud B., Andrikopoulos K., Shapiro S.D., Bunton T., et al. Pathogenetic sequence for aneurysm revealed in mice underexpressing fibrillin-1. Proc Natl Acad Sci U S A 96 (1999) 3819-3823
16. Kelleher C.M., McLean S.E., and Mecham R.P. Vascular extracellular matrix and aortic development. Curr Top Dev Biol 62 (2004) 153-188
17. Bunton T.E., Biery N.J., Myers L., Gayraud B., Ramirez F., and Dietz H.C. Phenotypic alteration of vascular smooth muscle cells precedes elastolysis in a mouse model of Marfan syndrome. Circ Res 88 (2001) 37-43
18. Guo G., Booms P., Halushka M., Dietz H.C., Ney A., Stricker S., et al. Induction of macrophage chemotaxis by aortic extracts of the mgR Marfan mouse model and a GxxPG-containing fibrillin-1 fragment. Circulation 114 (2006) 1855-1862
19. Segura A.M., Luna R.E., Horiba K., Stetler-Stevenson W.G., McAllister Jr. H.A., Willerson J.T., et al. Immunohistochemistry of matrix metalloproteinases and their inhibitors in thoracic aortic aneurysms and aortic valves of patients with Marfan's syndrome. Circulation 98 (1998) II331-II338
20. Matyas G., Alonso S., Patrignani A., Marti M., Arnold E., Magyar I., et al. Large genomic fibrillin-1 (FBN1) gene deletions provide evidence for true haploinsufficiency in Marfan syndrome. Hum Genet 122 (2007) 23-32
21. Hutchinson S., Furger A., Halliday D., Judge D.P., Jefferson A., Dietz H.C., et al. Allelic variation in normal human FBN1 expression in a family with Marfan syndrome: a potential modifier of phenotype?. Hum Mol Genet 12 (2003) 2269-2276
22. Pereira L., D'Alessio M., Ramirez F., Lynch J.R., Sykes B., Pangilinan T., et al. Genomic organization of the sequence coding for fibrillin, the defective gene product in Marfan syndrome. Hum Mol Genet 2 (1993) 1762
23. Ng C.M., Cheng A., Myers L.A., Martinez-Murillo F., Jie C., Bedja D., et al. TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest 114 (2004) 1586-1592
24. Lim D.S., Lutucuta S., Bachireddy P., Youker K., Evans A., Entman M., et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 103 (2001) 789-791
25. Lavoie P., Robitaille G., Agharazii M., Ledbetter S., Lebel M., and Lariviere R. Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats. J Hypertens 23 (2005) 1895-1903
26. Everett A.D., Tufro-McReddie A., Fisher A., and Gomez R.A. Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-beta 1 expression. Hypertension 23 (1994) 587-592
27. Kubo A., Fukuda N., Teng J., Satoh C., Nakayama M., Kishioka H., et al. Angiotensin II regulates the cell cycle of vascular smooth muscle cells from SHR. Am J Hypertens 13 (2000) 1117-1124
28. Daugherty A., Manning M.W., and Cassis L.A. Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis. Br J Pharmacol 134 (2001) 865-870
29. Rossi-Foulkes R., Roman M.J., Rosen S.E., Kramer-Fox R., Ehlers K.H., O'Loughlin J.E., et al. Phenotypic features and impact of beta blocker or calcium antagonist therapy on aortic lumen size in the Marfan syndrome. Am J Cardiol 83 (1999) 1364-1368
30. Loeys B.L., Chen J., Neptune E.R., Judge D.P., Podowski M., Holm T., et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 37 (2005) 275-281
31. Matyas G., Arnold E., Carrel T., Baumgartner D., Boileau C., Berger W., et al. Identification and in silico analyses of novel TGFBR1 and TGFBR2 mutations in Marfan syndrome-related disorders. Hum Mutat 27 (2006) 760-769